Elicio Therapeutics, Inc. (ELTX) intrinsic value & 10-year financials
Elicio Therapeutics, Inc. (ELTX) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.56
- Market cap
- $23.9M
- Revenue (FY2025)
- —
- Revenue growth (7-yr CAGR)
- 245.3%
- ROIC (10-yr avg)
- -1816.7%
- Free cash flow (FY2025)
- -$37.0M
ELTX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$39.6M | -$2.58 | -$37.0M | — | 1045.1% |
| FY2024 | — | -$51.9M | -$4.25 | -$37.2M | — | -12945.6% |
| FY2023 | — | -$35.2M | -$6.96 | -$32.8M | — | -1512.1% |
| FY2022 | $2.3M | -$38.8M | -$1.29 | — | -1721.9% | 2403.5% |
| FY2021 | $27.5M | -$54.6M | -$1.93 | -$53.0M | -142.9% | 63.3% |
| FY2020 | $193.0K | -$80.1M | -$2.71 | -$22.9M | -28638.9% | 45.8% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Elicio Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Elicio Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -0.2% ROIC.
Elicio Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Elicio Therapeutics, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-85.70 per share.